Baird Reiterates Outperform Rating on Biohaven Pharma (BHVN), "no change to outlook"
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $42.00 price target on Biohaven Pharma (NYSE: BHVN).The analyst commented: "No ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
